Purpose of investigation. To investigate the prognosis of high-risk early-stage cervical cancer patients who did not receive postoperative concurrent chemoradiotherapy (CCRT). Materials and Methods. The characteristics and outcomes of high-risk early-stage cervical cancer patients who did not receive postoperative CCRT were collected. They were separated into two groups according to the type of adjuvant treatment: no further therapy (NFT group) or chemotherapy (chemotherapy group), and the clinico-pathological characteristics, recurrence rate, progression-free survival (PFS), and overall survival (OS) were investigated. Results. A total of 23 patients were included. After a median follow-up period of 115 months, 19 had developed recurrent disease, and 17 had died of disease progression. The median PFS and OS of all patients were ten and 29 months, respectively. The recurrence rate of the NFT group (n=10) was similar to that of the chemotherapy group (n=13) (80% vs. 85%, p > 0.05). Although the PFS and OS of the chemotherapy group were slightly longer than those of the NFT group, the differences were not statistically significant (PFS, 10 vs. 36 months, p > 0.05; OS, 28 vs. 59 months p > 0.05). Conclusion. High-risk early-stage cervical cancer patients who did not receive postoperative CCRT have dismal prognosis irrespective of the type of adjuvant treatment.